Lytus Technologies Holdings PTV. Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYT research report →
Price Chart
About the company
Lytus Technologies Holdings Private Limited functions as a platform services company, delivering content streaming and telecasting to users throughout India. Its primary offering, the Lytus platform, provides a diverse array of streaming options along with telemedicine services, enhanced by local assistance through health centers. Customers gain access to these comprehensive services, including remote medical consultations, by connecting to the platform via CPE devices or set-top boxes.
- CEO
- Dharmesh Pandya
- IPO
- 2022
- Employees
- 3
- HQ
- Mumbai, IN
Get TickerSpark's AI analysis on LYT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.93M
- P/E
- 0.33
- PEG
- 0.00
- P/S
- 0.46
- P/B
- 0.01
- EV/EBITDA
- 5.93
- Div Yield
- 0.00%
- Gross Margin
- 16.75%
- Op Margin
- 14.71%
- Net Margin
- 1.35%
- ROE
- 2.72%
- ROIC
- 13.18%
Latest fiscal year · YoY change
- Revenue
- $21.36M+12.4%
- Gross Profit
- $3.58M-20.3%
- Op Income
- $3.14M
- Net Income
- $287.67K+112.3%
- EPS
- $0.30+107.8%
- OCF Growth
- -23.2%
- FCF Growth
- +89.1%
- 52W High
- $5.00
- 52W Low
- $0.01
- 50D MA
- $0.13
- 200D MA
- $1.19
- Beta
- 2.22
- RSI (14)
- 36
- Avg Volume
- 36.13M
No earnings-call transcripts are available for LYT yet.
- Free Float
- 4.9%
- Shares Outstanding
- 101.16M
- Float Shares
- 4.93M
of shares held by institutions
9 13F filers
Our LYT coverage
Recent articles, reports, and earnings notes.
No research on LYT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYT report →PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
businesswire.com · Feb 19
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
businesswire.com · Dec 8
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
businesswire.com · Dec 5
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
businesswire.com · Sep 29
Lytus Technologies announces 24% Revenue Growth for H1 FY2025
globenewswire.com · Mar 17
Lytus Technologies Expands HealthTech Initiatives and Strengthens Growth Trajectory
globenewswire.com · Feb 6
Lytus Technologies Expands Its Footprint into Healthcare with Cutting-Edge Patient-Centric HealthTech Platform
globenewswire.com · Jan 28
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
businesswire.com · Dec 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.